

## In This Issue

### Link Category Title

Medical Coding Resources

AMPM Policy Manual

FFS Provider Manual

### Contact Us

[codingpolicyquestions@azahcccs.gov](mailto:codingpolicyquestions@azahcccs.gov)

## 2023 New CPT HCPCS Codes

The new 2023 CPT and HCPCS codes and all new modifiers will be in the system for all dates of service on or after 01/01/2023.

Please make sure you are reviewing all the coding changes in your CPT and HCPCS books.

The following new 2023 CPT/HCPCS codes **will not be covered at this time**,

81418 Genomic sequence analysis panel of at least 6 genes associated with drug metabolism,

81441 Gene sequence analysis panel at least 30 genes associated with inherited bone marrow failure syndromes,

81449 Targeted genomic sequence analysis panel of RNA of 5-50 genes associated with solid organ neoplasm,

81451 Targeted genomic sequence analysis panel of RNA of 5-50 genes associated with blood and lymphatic system disorders,

81456 Targeted genomic sequence analysis panel of RNA of 51 or greater genes associated with blood and lymphatic system disorders

90678 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use (Not FDA approved),

0355U Apol1 (apolipoprotein 11) (eg, chronic kidney disease), risk variants (g1, g2),

0356U Oncology (oropharyngeal), evaluation of 17 dna biomarkers using droplet digital pcr (ddpcr), cell-free dna, algorithm reported as a prognostic risk score for cancer recurrence,

0357U Oncology (melanoma), artificial intelligence (ai)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents,

0358U Neurology (mild cognitive impairment), analysis of b-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative,

0359U Oncology (prostate cancer), analysis of all prostate-specific antigen (psa) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk

of cancer,

0360U Oncology (lung), enzyme-linked immunosorbent assay (elisa) of 7 autoantibodies (p53, ny-eso-1, cage, gbu4-5, sox2, mage a4, and hud), plasma, algorithm reported as a categorical result for risk of malignancy,

0361U Neurofilament light chain, digital immunoassay, plasma, quantitative,

0362U Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment rna sequencing of 82 content genes and 10 housekeeping genes, formalin-fixed paraffin embedded (ffpe) tissue, algorithm reported as one of three molecular subtypes,

0363U Oncology (urothelial), mrna, gene expression profiling by real-time quantitative pcr of 5 genes (mdk, hoxa13, cdc2 [cdk1], igfbp5, and cxcr2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma,

0738T Treatment planning for destruction of prostate cancer by magnetic field induction, using data from previously performed MRI,

0739T Destruction of prostate cancer by magnetic field induction,

0740T Set-up and patient education for remote autonomous algorithm-based recommendation system for insulin dose calculation and titration,

0741T Provision of software, data collection, transmission, and storage for remote autonomous algorithm-based recommendation system for insulin dose calculation and titration, each 30 days,

0742T SPECT measurement of blood flow to heart muscle,

0743T Bone strength and fracture-risk assessment with assessment for broken spine bones,

0744T Insertion of bioprosthetic valve in vein of thigh (femoral vein),

0745T Noninvasive localization and mapping of heart tissue causing abnormal heart rhythm for radiation treatment for focal destruction of arrhythmia site,

0746T Conversion of localization and mapping of heart tissue causing abnormal heart rhythm into a multidimensional radiation treatment plan for focal destruction of arrhythmia site,

0747T Radiation treatment for focal destruction of arrhythmia site causing abnormal heart rhythm,

0748T Injections of stem cell product into soft tissue around abnormal drainage tract next to anus,

0749T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD),

0750T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) with single-view digital X-ray of hand,

0751T Digitization of glass microscope slides for level II surgical pathology,

0752T Digitization of glass microscope slides for level III surgical pathology,  
0753T Digitization of glass microscope slides for level IV surgical pathology,  
0754T Digitization of glass microscope slides for level V surgical pathology  
0755T Digitization of glass microscope slides for level VI surgical pathology,  
0756T Digitization of glass microscope slides for Group I special stain for microorganisms,  
0757T Digitization of glass microscope slides for Group II special stain,  
0758T Digitization of glass microscope slides for histochemical special stain on frozen tissue block,  
0759T Digitization of glass microscope slides for Group III special stain,  
0760T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, initial single antibody stain procedure,  
0761T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, each additional single antibody stain procedure,  
0762T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, each multiplex antibody stain procedure,  
0763T Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry, each manual single antibody stain procedure,  
0764T Assistive algorithmic EKG risk-based assessment for heart dysfunction based on EKG performed at same time,  
0765T Assistive algorithmic EKG risk-based assessment for heart dysfunction based on previous EKG,  
0766T Transcutaneous magnetic stimulation of peripheral nerve by focused low-frequency electromagnetic pulse, initial treatment on first nerve,  
0767T Transcutaneous magnetic stimulation of peripheral nerve by focused low-frequency electromagnetic pulse, initial treatment on additional nerve,  
0768T Transcutaneous magnetic stimulation of peripheral nerve by focused low-frequency electromagnetic pulse, subsequent treatment on first nerve,  
0769T Transcutaneous magnetic stimulation of peripheral nerve by focused low-frequency electromagnetic pulse, subsequent treatment on additional nerve,  
0770T Virtual reality technology to assist therapy,  
0771T Virtual reality (VR) procedural dissociation services provided by same health care professional performing diagnostic or therapeutic procedure VR procedural dissociation supports, initial 15 minutes, patient age 5 years or older,  
0772T Virtual reality (VR) procedural dissociation services provided by same health care professional performing diagnostic or therapeutic procedure VR procedural dissociation supports, additional 15 minutes,  
0773T Virtual reality (VR) procedural dissociation services provided by different health

care professional than health care professional performing diagnostic or therapeutic procedure VR procedural dissociation supports, initial 15 minutes, patient age 5 years or older,

0774T Virtual reality (VR) procedural dissociation services provided by different health care professional than health care professional performing diagnostic or therapeutic procedure VR procedural dissociation supports, additional 15 minutes,

0775T Fusion of sacroiliac joint between spine and pelvis with bone graft, accessed through skin using imaging guidance,

0776T Therapeutic induction of low temperature in brain, 30 minutes of treatment,

0777T Real-time pressure-sensing epidural guidance system,

0778T Surface mechanomyography (sMMG) with application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function,

0779T Study of gastrointestinal muscle electric activity of stomach through large intestine,

0780T Instillation of stool microorganism suspension via rectal enema into lower digestive tract,

0781T Insertion of protection device in esophagus and radiofrequency destruction of nerves to lung in mainstem airway on one side of body using endoscope,

0782T Insertion of protection device in esophagus and radiofrequency destruction of nerves to lung in both mainstem airways using endoscope,

0783T Set-up, calibration, and patient education on use of equipment or stimulation of nerve to external ear and surrounding area (auricular nerve) through skin,

C7509 Bronchoscopy, rigid or flexible, diagnostic with cell washing(s) when performed, with computer-assisted image-guided navigation, including fluoroscopic guidance when performed,

C7510 Bronchoscopy, rigid or flexible, with bronchial alveolar lavage(s), with computer-assisted image-guided navigation, including fluoroscopic guidance when performed,

C7511 Bronchoscopy, rigid or flexible, with single or multiple bronchial or endobronchial biopsy(ies), single or multiple sites, with computer-assisted image-guided navigation, including fluoroscopic guidance when performed,

D0387 Intraoral tomosynthesis - comprehensive series of radiographic images - image capture only,

D0801 3d dental surface scan - direct,

D0802 3d dental surface scan - indirect,

D0803 3d facial surface scan - direct,

D0804 3d facial surface scan - indirect,

D1781 Vaccine administration - human papillomavirus - dose 1,

D1782 Vaccine administration - human papillomavirus - dose 2,  
D1783 Vaccine administration – human papillomavirus - dose 3,  
D6106 Guided tissue regeneration - resorbable barrier, per implant,  
D6107 Guided tissue regeneration - non-resorbable barrier, per implant,  
D9953 Reline custom sleep apnea appliance (indirect),  
Q4262 Dual layer impax membrane, per square centimeter,  
Q4263 Surgraft tl, per square centimeter,  
Q4264 Cocoon membrane, per square centimeter,  
Q5126 Injection, bevacizumab-maly, biosimilar, (alymysys), 10 mg.

---

## Evaluation and Management Codes

The American Medical Association (AMA) updated the coding guidelines for these codes. The POS and modifiers on the E/M codes are being updated to reflect these changes. Please refer to the 2023 CPT book for these updated guidelines or you can find a copy of the changes on the AMA website.

---

## Telehealth for 2023

The AHCCCS Telehealth Code Set will be updated once the PHE has ended, including the removal of codes that have an in-person requirement. Please watch for these updates after the PHE end date has been announced.

---

## New Modifiers for 2023

The following modifiers are new for 2023:

**AB** Audiology service furnished personally by an audiologist without a physician/npp order for non-acute hearing assessment unrelated to disequilibrium, or hearing aids, or examinations for the purpose of prescribing, fitting, or changing hearing aids; service may be performed once every 12 months, per beneficiary,

**JZ** Zero drug amount discarded/not administered to any patient (informational only),

**LU** Fractionated payment of car-t therapy. AHCCCS will not be utilizing this modifier for Car-T Therapy. (AHCCCS will not utilize this modifier)

---

## Reference Table Update Request

Please remember to use the Reference Table Update Request form found on the Medical Coding Resources page. This is a Word document that must be filled out including the date you wish us to consider. Also, please send the Word document to the email address

listed in the instructions.

---

## Email addresses:

Coding related to table updates should be sent to the Medical Coding Unit at [codingpolicyquestions@azahcccs.gov](mailto:codingpolicyquestions@azahcccs.gov).

Rates related questions should be submitted to [ffsrates@azahcccs.gov](mailto:ffsrates@azahcccs.gov).

FFS Provider Training or billing questions should be submitted to [providertrainingffs@azahcccs.gov](mailto:providertrainingffs@azahcccs.gov).

AHCCCS policies can be found at [www.azahcccs.gov/PlansProviders/GuidesManualsPolicies/index.html](http://www.azahcccs.gov/PlansProviders/GuidesManualsPolicies/index.html).